DON Composition for Long-Term Inflammatory Skin Disease Control

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for inflammatory skin diseases like atopic dermatitis and psoriasis, such as steroids and calcineurin inhibitors, have significant side effects and are not suitable for long-term use, especially in children and infants, necessitating a safer and more economical alternative.

Innovation Solution

A pharmaceutical composition containing 6-diazo-5-oxo-L-norleucine or its pharmaceutically acceptable salt, which inhibits chemokine secretion, keratinocyte hyperproliferation, mast cell infiltration, and immune cell penetration by targeting histone acetylation and glutamine metabolism.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If steroids are used to treat inflammatory skin diseases, then the anti-inflammatory effect is improved, but severe hypersensitivity reactions and skin thinning occur

Engineering Contradiction:

Improveanti-inflammatory effectVSAvoidhypersensitivity reaction and skin thinning

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the molecular target from immune cell activity (conventional steroid mechanism) to histone acetylation and glutamine metabolism. By introducing 6-diazo-5-oxo-L-norleucine that specifically inhibits histone acetylation and glutamine metabolism, the treatment achieves anti-inflammatory effects through a completely different biochemical parameter, avoiding the harmful side effects of conventional steroids while maintaining therapeutic efficacy.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If calcineurin inhibitors are used to treat inflammatory skin diseases, then the anti-inflammatory effect is improved, but cancer risk increases

Engineering Contradiction:

Improveanti-inflammatory effectVSAvoidcancer risk

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent shifts the therapeutic mechanism from immune cell proliferation inhibition (calcineurin inhibitor mechanism) to histone acetylation and glutamine metabolism inhibition. This parameter change results in anti-inflammatory effects without the cancer-risk associated with long-term calcineurin inhibitor use, making the treatment safer for children and infants.

Inventive Principle:

Principle #35Parameter changes

3Duration of action of stationary object

If steroids are used for long term, then the anti-inflammatory effect is maintained, but skin thinning and discoloration worsen

Engineering Contradiction:

Improveduration of anti-inflammatory effectVSAvoidskin thinning and discoloration

Core Design Contradiction:

Duration of action of stationary objectVSObject-affected harmful factors

Solution Approach 1:

The patent introduces a novel mechanism targeting histone acetylation and glutamine metabolism that allows for long-term use without the cumulative skin damage associated with prolonged steroid therapy. The specific inhibition of these metabolic pathways provides sustained anti-inflammatory protection while preserving skin integrity.

Inventive Principle:

Principle #35Parameter changes

4Reliability

If conventional therapies are used, then the symptom relief is achieved, but the disease recurs when drug use is discontinued

Engineering Contradiction:

Improvesymptom reliefVSAvoiddisease recurrence

Core Design Contradiction:

ReliabilityVSStability of the object's composition

Solution Approach 1:

The patent targets fundamental cellular processes (histone acetylation and glutamine metabolism) that are centrally involved in inflammatory skin disease pathogenesis. By inhibiting these core metabolic pathways, the treatment achieves more stable and durable symptom relief compared to conventional therapies that provide only temporary relief, reducing disease recurrence when treatment is stopped.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The composition effectively treats inflammatory skin diseases with minimal side effects, allowing long-term use in young patients, including infants and toddlers, by inhibiting key inflammatory pathways and reducing symptoms like pruritus and secondary infections.

Implementation Method 1

inhibits chemokine secretion by inhibiting histone acetylation in keratinocytes and fibroblasts

Methodology Applied

Scientific EffectHistone acetylation inhibition:

Implementation Method 2

inhibits keratinocyte hyperproliferation and epithelial cell migration by inhibiting glutamine metabolism

Methodology Applied

Scientific EffectGlutamine metabolism inhibition:

Data Source

PatentUS20260021120A1Method for treating inflammatory skin disease using 6-diazo-5-oxo-l-norleucine

Publication Date: 2026.01.22 NATUREBLUE CO LTD

AI summary

The present application relates to a pharmaceutical composition for treatment or prevention of an inflammatory skin disease including atopic dermatitis and psoriasis, the pharmaceutical composition containing 6-diazo-5-oxo-L-norleucine or a pharmaceutically acceptable salt thereof.